Abstract:Polyglutamine (PolyQ) diseases include a group of inherited neurodegenerative disorders caused by unstable expansions of CAG trinucleotide repeats in the coding region of specific genes. Such genetic alterations produce abnormal proteins containing an unusually long PolyQ tract that renders them more prone to aggregate and cause toxicity. Although research in the field in the last years has contributed significantly to the knowledge of the biological mechanisms implicated in these diseases, effective treatments are still lacking. In this review, we revisit work performed in models of PolyQ diseases, namely the yeast Saccharomyces cerevisiae, the nematode worm Caenorhabditis elegans and the fruit fly Drosophila melanogaster, and provide a critical overview of the high-throughput unbiased genetic screens that have been performed using these systems to identify novel genetic modifiers of PolyQ diseases. These approaches have revealed a wide variety of cellular processes that modulate the toxicity and aggregation of mutant PolyQ proteins, reflecting the complexity of these disorders and demonstrating how challenging the development of therapeutic strategies can be. In addition to the unbiased large-scale genetic screenings in non-vertebrate models, complementary studies in mammalian systems, closer to humans, have contributed with novel genetic modifiers of PolyQ diseases, revealing neuronal function and inflammation as key disease modulators. A pathway enrichment analysis, using the human orthologues of genetic modifiers of PolyQ diseases clustered modifier genes into major themes translatable to the human disease context, such as protein folding and transport as well as transcription regulation. Innovative genetic strategies of genetic manipulation, together with significant advances in genomics and bioinformatics, are taking modifier genetic studies to more realistic disease contexts. The characterization of PolyQ disease modifier pathways is of extreme relevance to reveal novel therapeutic possibilities to delay disease onset and progression in patients.

Altered Metabolic Signaling and Potential Therapies in Polyglutamine Diseases

Transcriptional Dysregulation: A Therapeutic Target for Polyglutamine Diseases

Intracellular Degradation of Misfolded Proteins in Polyglutamine Neurodegenerative Diseases

The Expanding Clinical Universe of Polyglutamine Disease.

Polyglutamine (PolyQ) Diseases: Navigating the Landscape of Neurodegeneration

Modifier pathways in polyglutamine (PolyQ) diseases: from genetic screens to drug targets

Glutamine Improves Oxidative Stress through the Wnt3a/ β -Catenin Signaling Pathway in Alzheimer's Disease In Vitro and In Vivo.

Polyglutamine Protein Trafficking and Neurodegeneration

Synergistic Toxicity of Polyglutamine-Expanded TATA-Binding Protein in Glia and Neuronal Cells: Therapeutic Implications for Spinocerebellar Ataxia 17.

Glutamine stimulates the S6K/4E-BP branch of insulin signalling pathway to mitigate human poly(Q) disorders in Drosophila disease models

Nuclear Accumulation of Polyglutamine Disease Proteins and Neuropathology

A Synergistic Perspective on Theoretical and Experimental Approaches

Current Understanding on the Pathogenesis of Polyglutamine Diseases

Glutaminolysis is a Potential Therapeutic Target for Kidney Diseases

Glutamine Protects Against Oxidative Stress Injury Through Inhibiting the Activation of PI3K/Akt Signaling Pathway in Parkinsonian Cell Model

Extracellular Vesicles Physiological Role and the Particular Case of Disease-Spreading Mechanisms in Polyglutamine Diseases

Alleviating Neurodegeneration in Drosophila Models of PolyQ Diseases

[The Advances in Research on Phosphorylation of Polyglutamine Disease].

Autophagy and Polyglutamine Disease

Post-translational Regulation of GLT-1 in Neurological Diseases and Its Potential as an Effective Therapeutic Target

Viral-based animal models in polyglutamine disorders